DANIEL HA: Open Payments
NPI 1023503984 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$820 in 44 payments from 11 companies in 2025. Trend: 2023 $362 · 2024 $518 · 2025 $820
Food & beverage: $802Education: $18
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $182 |
| Alkermes, Inc. | 8 | $163 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| ABBVIE INC. | 4 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Noven Therapeutics, LLC | 1 | $24 |
Products named: TRINTELLIX, ARISTADA, FANAPT, VRAYLAR, REXULTI, LYBALVI, Qelbree, CAPLYTA.
Industry payments across TX — which companies pay providers there.
